Trial Profile
A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Acronyms Ro-ENKTL
- 09 Dec 2015 Results published in the Annals of Oncology
- 06 Aug 2013 New trial record